On Friday, Glenmark Pharmaceutical said that it has got final approval from the US health regulator for Voriconazole Tablets that is used for treating fungal infections.
Glenmark said in a BSE filing, “Glenmark Pharmaceuticals Inc., USA has been granted final approval by the US Food & Drug Administration (USFDA) for Voriconazole Tablets, the therapeutic equivalent to Vfend tablets.”
The approval is granted for tablets in 50 mg and 200 mg strengths.